Eli Lilly's retatrutide cuts knee osteoarthritis pain by up to 75.8% in Phase 3 trial
LLY•Eli Lilly said Phase 3 TRIUMPH-1 and TRIUMPH-4 trials found its investigational drug retatrutide reduced knee osteoarthritis pain and weight, with some participants finishing treatment without knee pain. The company will present the results, along with findings from a Taltz-Zepbound trial, at ACR Convergence Nov. 6-11, 2026.
1. Retatrutide trial results
Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed investigational retatrutide reduced knee osteoarthritis pain and weight; some participants finished treatment without knee pain.
2. Psoriatic arthritis study
In the Phase 3b TOGETHER-PsA trial, Taltz with Zepbound improved disease control versus Taltz alone at one year in adults with psoriatic arthritis and obesity. Eli Lilly will present the trial results at ACR Convergence, Nov. 6-11, 2026, in Orlando.
